# PCRX catalysts: Pacira BioSciences, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/pcrx/catalysts

> Pacira BioSciences, Inc. (PCRX) has 2 upcoming catalysts. The next is the zilretta primary completion, December 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Pacira BioSciences, Inc. |
| Ticker | PCRX (Nasdaq) |
| SEC CIK | 1396814 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/pcrx |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Feb 2024 | [Enekinragene inzadenovec FDA approval](https://sec-api.dev/pdufa/enekinragene-inzadenovec) | PCRX |  | completed, approved | "These increases were partially offset by the completion of pre-commercial scale-up activities of our enhanced, larger-scale EXPAREL manufacturing capacity at our Science Center Campus in San Diego, California, which the FDA approved in February 2024 and was placed into service in July 2024." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1396814/000139681425000102/pcrx-20250630.htm)) |
| September 30, 2024 | [Pacira BioSciences, Inc. FDA approval](https://sec-api.dev/companies/pcrx/catalysts) | PCRX |  | completed, approved | "(8) During the three months ended September 30, 2024, the United States Food and Drug Administration approved a generic competitor to EXPAREL and a U.S. District Court ruled that one of our patents was not valid." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1396814/000162828025050145/pcrx-09302025x991.htm)) |
| December 31, 2024 | [Pacira BioSciences, Inc. FDA approval](https://sec-api.dev/companies/pcrx/catalysts) | PCRX |  | completed, approved | "(7) During the year ended December 31, 2024, the U.S. Food and Drug Administration approved a generic competitor to EXPAREL and a U.S. District Court ruled that one of our patents was not valid." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1396814/000162828026012238/pcrx-12312025x991.htm)) |
| January 10, 2025 | [Pacira BioSciences, Inc. earnings report](https://sec-api.dev/companies/pcrx/catalysts) | PCRX |  | completed | "Pacira expects to report its complete financial results for the fourth quarter and full-year 2024, along with the company's financial guidance, later in the first quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1396814/000139681425000011/pcrx-2024revenuepressrelea.htm)) |
| Feb 2025 | [Enekinragene inzadenovec trial start](https://sec-api.dev/pdufa/enekinragene-inzadenovec) | PCRX |  | scheduled | "Table of Contents provides financial benefits with the elimination of future development and sales-based milestones including a $4.5 million milestone payment due upon initiation of the Phase 2 clinical trial of PCRX-201 that opened enrollment in February 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1396814/000139681425000041/pcrx-20241231.htm)) |
| February 27, 2025 | [Pacira BioSciences, Inc. earnings report](https://sec-api.dev/companies/pcrx/catalysts) | PCRX |  | completed | "Pacira BioSciences Reports Fourth Quarter and Full-Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1396814/000139681425000039/pcrx-12312024x991.htm)) |
| Apr 2025 | [Enekinragene inzadenovec trial start](https://sec-api.dev/pdufa/enekinragene-inzadenovec) | PCRX | osteoarthritis, or OA, of the knee | completed | "•In April 2025, we announced that the first patient was dosed in our Phase 2 ASCEND study evaluating the safety and efficacy of PCRX-201 for the treatment of OA of the knee." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1396814/000139681425000061/pcrx-20250331.htm)) |
| May 8, 2025 | [Pacira BioSciences, Inc. earnings report](https://sec-api.dev/companies/pcrx/catalysts) | PCRX |  | completed | "Pacira BioSciences Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1396814/000139681425000060/pcrx-3312025x991.htm)) |
| August 5, 2025 | [Pacira BioSciences, Inc. earnings report](https://sec-api.dev/companies/pcrx/catalysts) | PCRX |  | completed | "Pacira BioSciences Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1396814/000139681425000100/pcrx-6302025x991.htm)) |
| October 16, 2025 | [Zilretta primary completion](https://sec-api.dev/pdufa/zilretta) | PCRX | Osteoarthritis of Hip | withdrawn | "NCT06977568 (A Study to Evaluate an Intra-Articular Injection of ZILRETTA Versus Triamcinolone Acetonide, Immediate Release in Subjects With Osteoarthritis of the Hip): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-10-16 (ACTUAL); Lead Sponsor Pacira Pharmaceuticals, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06977568)) |
| November 6, 2025 | [Pacira BioSciences, Inc. earnings report](https://sec-api.dev/companies/pcrx/catalysts) | PCRX |  | completed | "Pacira BioSciences Reports Third Quarter 2025 Financial Results;" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1396814/000162828025050145/pcrx-09302025x991.htm)) |
| January 8, 2026 | [Pacira BioSciences, Inc. earnings report](https://sec-api.dev/companies/pcrx/catalysts) | PCRX |  | completed | "Pacira expects to report its complete financial results for the fourth quarter and full-year 2025, along with the company's financial guidance, later in the first quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1396814/000162828026001335/pcrx-2025revenuepressrelea.htm)) |
| February 26, 2026 | [Pacira BioSciences, Inc. earnings report](https://sec-api.dev/companies/pcrx/catalysts) | PCRX |  | completed | "Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1396814/000162828026012238/pcrx-12312025x991.htm)) |
| April 30, 2026 | [Pacira BioSciences, Inc. earnings report](https://sec-api.dev/companies/pcrx/catalysts) | PCRX |  | completed | "Pacira BioSciences Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1396814/000162828026028854/pcrx-03312026x991.htm)) |
| August 4, 2026 | [Pacira BioSciences, Inc. earnings report](https://sec-api.dev/companies/pcrx/catalysts) | PCRX |  | completed | "Pacira BioSciences Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1396814/000162828026052527/pcrx-06302026x991.htm)) |
| late 2026 | [Pacira BioSciences, Inc. topline data readout](https://sec-api.dev/companies/pcrx/catalysts) | PCRX |  | scheduled | "We have concluded enrollment in a Phase 3 registration study to evaluate the safety and efficacy of ZILRETTA for the management of OA pain of the shoulder and expect to report topline results before the end of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1396814/000162828026071136/pcrx-20260930.htm)) |
| late 2026 | [Pacira BioSciences, Inc. topline data readout](https://sec-api.dev/companies/pcrx/catalysts) | PCRX |  | scheduled | "The company expects to report topline results from Part A of the study near the end of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1396814/000162828025050145/pcrx-09302025x991.htm)) |
| late 2026 | [Enekinragene inzadenovec interim data readout](https://sec-api.dev/pdufa/enekinragene-inzadenovec) | PCRX |  | scheduled | "We remain on track to report results from a pre-specified interim analysis before the end of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1396814/000162828025050176/pcrx-20250930.htm)) |
| November 2026 | [Enekinragene inzadenovec (pcrx-201) primary completion](https://sec-api.dev/pdufa/enekinragene-inzadenovec-pcrx-201) | PCRX | Osteoarthritis (OA) of the Knee | scheduled | "NCT06884865 (A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor Pacira Pharmaceuticals, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06884865)) |
| Nov 2026 to Feb 2027 | [Enekinragene inzadenovec (pcrx-201) topline data readout](https://sec-api.dev/pdufa/enekinragene-inzadenovec-pcrx-201) | PCRX | Osteoarthritis (OA) of the Knee | scheduled | "NCT06884865 (A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor Pacira Pharmaceuticals, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06884865)) |
| December 2026 | [Zilretta primary completion](https://sec-api.dev/pdufa/zilretta) | PCRX | Glenohumeral Osteoarthritis | scheduled | "NCT06269705 (ZILRETTA in Subjects With Shoulder Osteoarthritis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Pacira Pharmaceuticals, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06269705)) |
| Dec 2026 to Mar 2027 | [Zilretta topline data readout](https://sec-api.dev/pdufa/zilretta) | PCRX | Glenohumeral Osteoarthritis | scheduled | "NCT06269705 (ZILRETTA in Subjects With Shoulder Osteoarthritis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Pacira Pharmaceuticals, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06269705)) |

## Drugs

- [Enekinragene inzadenovec](https://sec-api.dev/pdufa/enekinragene-inzadenovec): oa of the knee, osteoarthritis, or oa, of the knee
- [Enekinragene inzadenovec (pcrx-201)](https://sec-api.dev/pdufa/enekinragene-inzadenovec-pcrx-201): Osteoarthritis (OA) of the Knee
- [Zilretta](https://sec-api.dev/pdufa/zilretta): Osteoarthritis of Hip, Glenohumeral Osteoarthritis

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/pcrx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PCRX catalysts: Pacira BioSciences, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/pcrx/catalysts

```bibtex
@misc{secapidev_companies_pcrx_catalysts_20261116,
  title        = {PCRX catalysts: Pacira BioSciences, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/pcrx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_pcrx_catalysts_20261116","title":"PCRX catalysts: Pacira BioSciences, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/pcrx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
